Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03324360 : Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

Part I

- Adult participants of all ethnic groups/race categories (age >18yrs old)

- Informed consent

Part II & III

- Adult participants of all ethnic groups/race categories (age >18yrs old)

- Radiographic diagnosis of brain metastases and pathologic confirmation of a solid
cancer primary

- At least 1 intracranial metastasis ?1 cm in size

- Metastatic brain tumour amenable to Stereotactic radiosurgery or radiotherapy

- Participants on stable dexamethasone dose at the time of baseline MRI and 1-5 days
post-SRS MRI

- Estimated survival more than 6 months

- Informed consent

Exclusion Criteria:

- Prior brain radiotherapy

- The participant will also be asked to complete the standard MRI safety screening
questionnaire, prior to their research scan and participation in the study.

- Contraindications to MRI including:

- Participants weighing >136 kg (weight limit for the scanner tables)

- Participants with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable
electronic devices not compatible with MRI.

- Pregnant

- Claustrophobia

- Known adverse reactions to the contrast agent Gd-DTPA

- Inability to lie still for 45-60 minutes

- Participants with a high risk factor for nephrogenic systemic fibrosis (NFS),
including renal failure on dialysis, heart disease, diabetes, single kidney,
hypertension/hypotension, multiple myeloma, peripheral vascular disease, or taking of
specific medications (loop diuretics, NSAIDs, aminoglycosides, vancomycin,
amphotericin B, chemotherapy, or immunosuppressants).

- Participant declines the procedure or further procedures;

- Participant is not well enough to undergo MRI scanning;

- Participant is unable to complete the MRI procedure for any reason or is non-compliant
with MRI requirements.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557